MA50180A - Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté - Google Patents

Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté

Info

Publication number
MA50180A
MA50180A MA050180A MA50180A MA50180A MA 50180 A MA50180 A MA 50180A MA 050180 A MA050180 A MA 050180A MA 50180 A MA50180 A MA 50180A MA 50180 A MA50180 A MA 50180A
Authority
MA
Morocco
Prior art keywords
muté
kras
hla
restricted
class
Prior art date
Application number
MA050180A
Other languages
English (en)
Inventor
Gal Cafri
Paul F Robbins
Steven A Rosenberg
Rami Yoseph
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MA50180A publication Critical patent/MA50180A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
MA050180A 2017-09-20 2018-09-19 Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté MA50180A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762560930P 2017-09-20 2017-09-20

Publications (1)

Publication Number Publication Date
MA50180A true MA50180A (fr) 2021-05-26

Family

ID=63963389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050180A MA50180A (fr) 2017-09-20 2018-09-19 Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté

Country Status (17)

Country Link
US (2) US11306132B2 (fr)
EP (1) EP3684799A1 (fr)
JP (1) JP7256794B2 (fr)
KR (1) KR20200051804A (fr)
CN (1) CN111201237A (fr)
AR (1) AR112902A1 (fr)
AU (1) AU2018335274A1 (fr)
BR (1) BR112020005469A2 (fr)
CA (1) CA3076339A1 (fr)
CR (1) CR20240019A (fr)
EA (1) EA202090652A1 (fr)
IL (1) IL273254B2 (fr)
MA (1) MA50180A (fr)
MX (2) MX2020003117A (fr)
SG (1) SG11202002425PA (fr)
TW (1) TWI825029B (fr)
WO (1) WO2019060349A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3914270A4 (fr) * 2019-01-25 2023-01-11 The Trustees of the University of Pennsylvania Compositions et procédés de ciblage de ras mutants
JP2022542445A (ja) * 2019-07-30 2022-10-03 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体を識別する方法
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
CA3164986A1 (fr) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Dispositifs et procedes d'isolement de lymphocytes infiltrant les tumeurs et leurs utilisations
MX2022010191A (es) * 2020-02-19 2022-11-14 Aelin Therapeutics Moleculas dirigidas a proteina ras mutante.
US20230159614A1 (en) * 2020-02-26 2023-05-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
WO2021262829A2 (fr) * 2020-06-24 2021-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t limités au hla de classe i contre le cd20
KR20230043881A (ko) * 2020-07-13 2023-03-31 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 drb t 세포 수용체
WO2022015922A1 (fr) * 2020-07-16 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t drb à restriction hla de classe ii dirigés contre ras, comprenant une mutation g12v
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
CA3202725A1 (fr) * 2020-11-24 2022-06-02 Shanghai GenBase Biotechnology Co., Ltd. Peptide epitope mutant ras et recepteur de lymphocyte t reconnaissant un mutant ras
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors containing polycistronic cassettes and methods for using them
WO2023150562A1 (fr) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Méthodes d'activation et d'expansion de lymphocytes t
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
WO2024072954A1 (fr) * 2022-09-29 2024-04-04 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Peptide d'épitope pan-cancereux traité par plasma atmopsherique froid à l'intérieur de la protéine du collagène de type vi a-3 (col6a3) utilisé en tant que vaccin anticancereux

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (fr) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de mise en croissance de lymphocytes infiltrant une tumeur dans contenants perméables au gaz
CA2963362A1 (fr) * 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedes d'isolement de recepteurs des lymphocytes t presentant une specificite antigenique pour une mutation specifique du cancer
HUE065689T2 (hu) * 2014-11-26 2024-06-28 The United States Of America Anti-mutált KRAS T sejt receptorok
MX2018000777A (es) * 2015-07-22 2018-03-23 Araxes Pharma Llc Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
EP3350213B1 (fr) 2015-09-15 2021-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t reconnaissant les gènes kras mutés limités en hla-cw8
SI3494133T1 (sl) 2016-08-02 2022-11-30 The U.S.A. as represented by the Secretary Department of Health and Human Services Office of Technology Transfer, National Institutes of Health Anti-Kras-G12D T-celični receptorji

Also Published As

Publication number Publication date
AU2018335274A1 (en) 2020-04-09
IL273254A (en) 2020-04-30
JP7256794B2 (ja) 2023-04-12
WO2019060349A1 (fr) 2019-03-28
US20220204584A1 (en) 2022-06-30
IL273254B2 (en) 2024-09-01
KR20200051804A (ko) 2020-05-13
IL273254B1 (en) 2024-05-01
BR112020005469A2 (pt) 2020-09-29
EP3684799A1 (fr) 2020-07-29
CN111201237A (zh) 2020-05-26
US11306132B2 (en) 2022-04-19
US20190085046A1 (en) 2019-03-21
TWI825029B (zh) 2023-12-11
SG11202002425PA (en) 2020-04-29
MX2020003117A (es) 2020-08-20
MX2024004610A (es) 2024-04-30
CA3076339A1 (fr) 2019-03-28
JP2020534828A (ja) 2020-12-03
EA202090652A1 (ru) 2020-08-21
CR20240019A (es) 2024-02-15
TW201920251A (zh) 2019-06-01
AR112902A1 (es) 2019-12-26

Similar Documents

Publication Publication Date Title
MA50180A (fr) Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté
MA44608A (fr) Récepteurs des lymphocytes t
MA47359A (fr) Récepteurs de lymphocytes t à appariement amélioré
MA50651A (fr) Récepteurs de lymphocytes t reconnaissant p53 mutée
DK3642224T3 (da) T-cellereceptorer
MA49236A (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
DK3394094T3 (da) T-celle receptorer specifikke for ny-eso-1 tumor antigen-hla-a*02 komplekset
DK3440102T3 (da) T-cellereceptorer
MA49503A (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
DK3455257T3 (da) Anti-pd-l1-antistoffer
EP3858852C0 (fr) Récepteur de lymphocytes t reconnaissant un antigène ssx2
DK3149031T3 (da) Anti-human papillomavirus 16 e7 t-cellereceptorer
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
DK3820873T3 (da) Selektive østrogenreceptornedbrydere
EP3475413C0 (fr) Lymphocytes t génétiquement modifiés
ZA202101537B (en) Anti-trem-2 agonist antibodies
EP3146079A4 (fr) Procédés permettant de déterminer des paires de chaînes des récepteurs de lymphocytes
DK3820874T3 (da) Selektive estrogenreceptornedbrydere
UA39585S (uk) Упаковка для сигарет
ITUB20160992A1 (it) Dispositivo separatore per gas blow-by
IL280367A (en) CD226 agonist antibodies
EP3884448C0 (fr) Systeme d'acheminement d'objets a initiation de cycle d'acheminement simplifie
IL279621A (en) Cancer-specific T-cell receptors
DK3629431T3 (da) Kabelfrigørelsesanordning
PL3776772T3 (pl) Mostek rozdzielający do łańcucha energetycznego